Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
7
TPST Quote, Financials, Valuation and Earnings
Last price:
$2.83
Seasonality move
:
-3.21%
Day range:
$2.83 - $3.05
52-week range:
$2.83 - $13.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.69x
Volume:
78.8K
Avg. volume:
190.9K
1-year change:
-73.29%
Market cap:
$10.8M
Revenue:
--
EPS (TTM):
-$10.10
Analysts' Opinion
-
Consensus RatingTempest Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.00, Tempest Therapeutics, Inc. has an estimated upside of 208.22% from its current price of $2.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $2.92.
Fair Value
-
According to the consensus of 2 analysts, Tempest Therapeutics, Inc. has 208.22% upside to fair value with a price target of $9.00 per share.
TPST vs. S&P 500
-
Over the past 5 trading days, Tempest Therapeutics, Inc. has underperformed the S&P 500 by -6.05% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Tempest Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tempest Therapeutics, Inc. revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Tempest Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Tempest Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Tempest Therapeutics, Inc. reported earnings per share of -$0.79.
Enterprise value:
11.6M
EV / Invested capital:
0.79x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$250K
Return On Assets:
-118.88%
Net Income Margin (TTM):
--
Return On Equity:
-311.64%
Return On Invested Capital:
-148.84%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$2.1M | -$426K | -$250K | -$98K | -$66K | |
| Operating Income | -$30.6M | -$35.6M | -$36.4M | -$10.6M | -$3.6M | |
| EBITDA | -$28.5M | -$35.2M | -$36.2M | -$10.5M | -$3.5M | |
| Diluted EPS | -$2.44 | -$1.54 | -$10.10 | -$0.41 | -$0.79 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62.6M | $60.3M | $12.3M | $23.6M | $8.1M | |
| Total Assets | $67.1M | $63.2M | $24M | $33.8M | $17.1M | |
| Current Liabilities | $6.2M | $24.1M | $7.4M | $14M | $3.5M | |
| Total Liabilities | $23.6M | $36.4M | $25.2M | $22.4M | $10.8M | |
| Total Equity | $43.5M | $26.8M | -$1.2M | $11.5M | $6.3M | |
| Total Debt | $17.4M | $15.8M | $19.9M | $16.9M | $7.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.7M | -$29.1M | -$33.4M | -$10.2M | -$6.8M | |
| Cash From Investing | -$519K | -$439K | -$3K | -$15K | -- | |
| Cash From Financing | -$3.5M | $40.9M | $18.4M | $1.5M | $13K | |
| Free Cash Flow | -$28.2M | -$29.5M | -$33.4M | -$10.2M | -$6.8M | |
TPST
Sector
Market Cap
$10.8M
$27.9M
Price % of 52-Week High
21.39%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-65.25%
-1.55%
1-Year Price Total Return
-73.29%
-17.49%
Beta (5-Year)
-2.434
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.02
200-day SMA
Sell
Level
$7.85
Bollinger Bands (100)
Sell
Level
5.08 - 11.3
Chaikin Money Flow
Sell
Level
-32.6K
20-day SMA
Sell
Level
$3.08
Relative Strength Index (RSI14)
Sell
Level
27.62
ADX Line
Sell
Level
27.59
Williams %R
Neutral
Level
-77.5
50-day SMA
Sell
Level
$6.32
MACD (12, 26)
Buy
Level
0.84
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
109.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.3816)
Sell
CA Score
(Annual)
Level (-4.5204)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.7698)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
Stock Forecast FAQ
In the current month, TPST has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TPST average analyst price target in the past 3 months is $9.00.
-
Where Will Tempest Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tempest Therapeutics, Inc. share price will rise to $9.00 per share over the next 12 months.
-
What Do Analysts Say About Tempest Therapeutics, Inc.?
Analysts are divided on their view about Tempest Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tempest Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Tempest Therapeutics, Inc.'s Price Target?
The price target for Tempest Therapeutics, Inc. over the next 1-year time period is forecast to be $9.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TPST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tempest Therapeutics, Inc. is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of TPST?
You can purchase shares of Tempest Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tempest Therapeutics, Inc. shares.
-
What Is The Tempest Therapeutics, Inc. Share Price Today?
Tempest Therapeutics, Inc. was last trading at $2.83 per share. This represents the most recent stock quote for Tempest Therapeutics, Inc.. Yesterday, Tempest Therapeutics, Inc. closed at $2.92 per share.
-
How To Buy Tempest Therapeutics, Inc. Stock Online?
In order to purchase Tempest Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TPST Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TPST
Sector
P/E ratio
--
23.75x
PEG ratio
0.00x
-0.01x
P/B ratio
1.69x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
TPST
Sector
Revenue growth
--
4.6%
Earnings growth
-93.33%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$3.27
-$0.21
Profitability
TPST
Sector
Profitability FY 2024
-$389K
$3.6M
Return on invested capital
-148.84%
-31.84%
Return on assets
-118.88%
-27.96%
Return on equity
-311.64%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
TPST
Sector
Total cash
$7.5M
$26.3M
Short term investments
--
$25.7M
Total assets
$44M
$76.9M
Long term debt
$7.3M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
